Placebo controlled trials in neuromyelitis optica are needed and ethical (Q26852547)

Multiple Sclerosis and Related Disorders

PubMed

published in

1 reference

1 reference

1 reference

536-45

1 reference

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Neuromyelitis optica treatment: analysis of 36 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Failure of natalizumab to prevent relapses in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Comment on neuromyelitis optica: potential roles for intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Variable results after rituximab in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

The effect of intravenous immunoglobulin on neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Equipoise and the ethics of clinical research

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

A Review of Cases of Neuromyelitis Optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

EFNS guidelines on diagnosis and management of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Impact of rituximab on relapse rate and disability in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

What does the medical profession mean by "standard of care?"

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

An open label study of the effects of rituximab in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Levels of evidence: Taking Neurology to the next level.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

A population-based study of neuromyelitis optica in Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

The clinical course of neuromyelitis optica (Devic's syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.MSARD.2015.07.017

7 January 2021

10.1016/J.MSARD.2015.07.017

Identifiers

DOI

0 references

PubMed publication ID

26590660

1 reference